ENOV Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

585.21M

+4.32%

0.817

-16.59%

582.65M

+4.26%

0.762

-5.87%

592.87M

+5.02%

0.859

+8.8%

Estimates Revision

The market is revising Upward the revenue expectations for Enovis Corporation (ENOV) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by -8.10%.

Revenue Estimates for FY2025

Revise Upward

+0.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.89%

In Past 3 Month

Stock Price

Go Down

-8.10%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 49.00 USD with a low forecast of 44.00 USD and a high forecast of 58.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

44.00

Averages

49.00

High

58.00

Current: 0.000

Low

44.00

Averages

49.00

High

58.00

BTIG

Ryan Zimmerman

initiated

$41

2026-01-06

New

Reason

BTIG

Ryan Zimmerman

Price Target

$41

2026-01-06

New

initiated

Reason

BTIG analyst Ryan Zimmerman initiated coverage of Enovis with a Buy rating and $41 price target. The multi-segment orthopedics company offers a full continuum of orthopedic care and this strategy has consistently enabled Enovis to outperform underlying end-markets, the analyst tells investors. The firm thinks the market has written off Enovis as under-scaled, weighted towards unattractive mature markets, subject to higher tariff exposure, and lacking significant cash flow, but the firm sees an attractive entry point and an improving financial profile, the analyst added.

Evercore ISI

Outperform

downgrade

$44 -> $40

2026-01-05

New

Reason

Evercore ISI

Price Target

$44 -> $40

2026-01-05

New

downgrade

Outperform

Reason

Evercore ISI lowered the firm's price target on Enovis to $40 from $44 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

Canaccord

Buy

downgrade

$58 -> $50

2025-12-17

Reason

Canaccord

Price Target

$58 -> $50

2025-12-17

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Enovis to $50 from $58 and keeps a Buy rating on the shares. The firm updated their model to largely reflect our new 2027 estimates, with some updates to 2026 estimates as well

Freedom Capital

NULL -> Buy

initiated

$45

2025-12-16

Reason

Freedom Capital

Price Target

$45

2025-12-16

initiated

NULL -> Buy

Reason

Freedom Capital initiated coverage of Enovis with a Buy rating and $45 price target.

Freedom Capital

Keith Hinton

Buy

initiated

$45

2025-12-16

Reason

Freedom Capital

Keith Hinton

Price Target

$45

2025-12-16

initiated

Buy

Reason

Freedom Capital analyst Keith Hinton initiated coverage of Enovis with a Buy rating and $45 price target. The orthopedics-focused medtech company's organic growth is rebounding in 2025 and the firm expects momentum to continue, the analyst tells investors. With shares trading near their post-spin lows and M&A dyssynergies diminishing, the firm views the company's improved competitive positioning as "underappreciated" and expects the multiple to start to close the gap with peers if the new CEO can continue to execute, the analyst added.

Baird

Outperform -> Outperform

downgrade

$50 -> $45

2025-11-07

Reason

Baird

Price Target

$50 -> $45

2025-11-07

downgrade

Outperform -> Outperform

Reason

Baird lowered the firm's price target on Enovis to $45 from $50 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results with consistency improved moving into 2026.

Valuation Metrics

The current forward P/E ratio for Enovis Corp (ENOV.N) is 8.15, compared to its 5-year average forward P/E of 20.60. For a more detailed relative valuation and DCF analysis to assess Enovis Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

20.60

Current PE

8.15

Overvalued PE

30.24

Undervalued PE

10.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.44

Current EV/EBITDA

6.92

Overvalued EV/EBITDA

18.33

Undervalued EV/EBITDA

6.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.59

Current PS

0.65

Overvalued PS

2.32

Undervalued PS

0.86

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ENOV News & Events

Events Timeline

No data

News

4.0

01-06Benzinga

Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets

5.0

01-05Globenewswire

Enovis Appoints Oliver Engert as Chief Administrative Officer to Drive Strategic Development

5.0

2025-12-08NASDAQ.COM

Enovis (ENOV) Insider Makes Significant Investment by Acquiring 2,468 Shares

People Also Watch

Frequently Asked Questions

What is Enovis Corp (ENOV) stock price today?

The current price of ENOV is 28.83 USD — it has increased 4.12 % in the last trading day.

What is Enovis Corp (ENOV)'s business?

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).

What is the price predicton of ENOV Stock?

What is Enovis Corp (ENOV)'s revenue for the last quarter?

Enovis Corp revenue for the last quarter amounts to 548.91M USD, increased 8.65 % YoY.

What is Enovis Corp (ENOV)'s earnings per share (EPS) for the last quarter?

Enovis Corp. EPS for the last quarter amounts to -9.99 USD, increased 1652.63 % YoY.

What changes have occurred in the market's expectations for Enovis Corp (ENOV)'s fundamentals?

How many employees does Enovis Corp (ENOV). have?

Enovis Corp (ENOV) has 7367 emplpoyees as of January 09 2026.

What is Enovis Corp (ENOV) market cap?

Today ENOV has the market capitalization of 1.65B USD.